Skip to main content

Perrigo Company(PRGO-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low9.23
Day High9.77
Open:9.56
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Perrigo Company

Select a category then submit the form to load news
Tipranks
Perrigo Earnings Call: Cost Cuts, Headwinds, and Hopes
Zacks Investment Research
PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View
PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View
Motley Fool
Perrigo (PRGO) Q4 2025 Earnings Call Transcript
MarketBeat
High Yield Revival: 3 Cash-Rich Dividend Payers on Sale
MarketBeat.com
Motley Fool
3 Healthcare Stocks Paying the Highest Dividends of 2026
Motley Fool
Why Hawaiian Electric Industries Stock Was Soaring Today
TheNewswire.com
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 16, 2026 in Perrigo Company plc Lawsuit - PRGO
TheNewswire.com
Shareholders of Perrigo Company plc Should Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your Rights - PRGO
Business Wire
Deadline Approaching: Perrigo Company plc (PRGO) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Business Wire
PRGO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Perrigo Company plc (PRGO) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Business Wire
Deadline Alert: Perrigo Company plc (PRGO) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Business Wire
Law Offices of Frank R. Cruz Encourages Perrigo Company plc (PRGO) Shareholders To Inquire About Securities Fraud Class Action
Business Wire
Rosen Law Firm Urges Perrigo Company plc (NYSE: PRGO) Investors with Large Losses to Contact the Firm for Information About Their Rights
Business Wire
Law Offices of Howard G. Smith Encourages Perrigo Company plc (PRGO) Shareholders to Inquire About Securities Fraud Class Action
Business Wire
PRGO CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Perrigo Company plc
Business Wire
PRGO CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit On Behalf Of Perrigo Company plc Shareholders
Newsfile
Did You Suffer Losses in Perrigo Company plc (PRGO)? Contact Levi & Korsinsky About Securities Fraud Claims
Business Wire
Securities Fraud Investigation Into Perrigo Company plc (PRGO) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Business Wire
Perrigo Company plc (PRGO) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Business Wire
Securities Fraud Investigation Into Perrigo Company plc (PRGO) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Newsfile
Levi & Korsinsky Investigates Perrigo Company plc (PRGO) Over Potential Securities Fraud Allegations
Tipranks
Perrigo Reports Q3 2025 Financial Results Amid Market Challenges
Tipranks
Perrigo Company Reports Q3 2025 Financial Results
Motley Fool
Perrigo (PRGO) Q3 2025 Earnings Call Transcript
Tipranks
Wall Street Analysts Are Neutral on Top Healthcare Picks
Motley Fool
DRZ Investment Advisors Initiated a Position in KB Home. Is the Stock a Buy?
Tipranks
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Perrigo Company (PRGO) and Abbott Laboratories (ABT)
Tipranks
J.P. Morgan Reaffirms Their Buy Rating on Perrigo Company (PRGO)
Tipranks
Canaccord Genuity Keeps Their Buy Rating on Perrigo Company (PRGO)
Tipranks
Jefferies Remains a Hold on Perrigo Company (PRGO)
Tipranks
J.P. Morgan Sticks to Its Buy Rating for Perrigo Company (PRGO)
Motley Fool
Perrigo (PRGO) Q2 EPS Rises 7.5%

Profile

Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International'(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.